



## Altimune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023

August 3, 2023 at 7:30 AM EDT

GAITHERSBURG, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2023 financial results on Thursday, August 10, 2023 and will provide a business update.

Altimune management will host a conference call at 8:30 am E.T. on August 10 to discuss financial results and provide a business update. The conference call will be webcast live on Altimune's Investor Relations website at <https://ir.altimmune.com/investors>.

Participants who would like to join the call may register [here](#) to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.

### About Altimune

Altimune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit [www.altimmune.com](http://www.altimmune.com).

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [Twitter](#)

### Investor and Media Contact:

Richard Eisenstadt  
Chief Financial Officer  
Phone: 240-654-1450  
[reisenstadt@altimmune.com](mailto:reisenstadt@altimmune.com)



Source: Altimune, Inc